Atea Pharmaceuticals, Inc. Cash Flow Statement
AVIR|3 years of annual SEC 10-K data (FY2020-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$121M
FY2022
Free Cash Flow
-$123M
FY2022
Capital Expenditures
$2M
Cash used for long-term assets
Dividends Paid
N/A
FY2022
Atea Pharmaceuticals, Inc. used $121M in operating cash flow and negative free cash flow of $123M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Net Income | -$115.9M | -$14.0M | -$9.1M |
| Depreciation & Amortization | $260.0K | $17.0K | $17.0K |
| Operating Cash Flow | -$121.0M | -$12.8M | -$7.9M |
| Capital Expenditures | $1.9M | $2.0K | $12.0K |
| Free Cash Flow | -$122.9M | -$12.8M | -$7.9M |
| FCF Margin | - | -26.4% | -16.3% |